Key Study Information:

  • Treatment Area:

    Parkinson's Disease

  • Study Aim:

    To advance our understanding of Parkinson’s Disease and accelerate the development of advanced therapies to improve outcomes for patients.

  • Sponsor/Owner:

    Queen Mary University of London

  • Goal:

    Ongoing patient recruitment of patient's diagnosed with Parkinson's Disease.

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    Multiple Sclerosis

  • Study Aim:

    To discover whether the genes that contribute to MS risk are the same or different for people of non-European ancestry, with a focus on people from African & South Asian backgrounds.

  • Sponsor/Owner:

    Queen Mary University of London

  • Goal:

    400 patients

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    Alopecia Areata

  • Study Aim:

    To assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.

  • Sponsor/Owner:

    Soterios

  • Goal:

    100 patients with mild to moderate Alopecia

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    Chronic Kidney Disease and Pruritus

  • Study Aim:

    To evaluate the efficacy and safety of MC2-25 Cream and MC2-25 vehicle in subjects with chronic kidney disease-associated pruritus (CKD aP).

  • Sponsor/Owner:

    MC2 Therapeutics

  • Goal:

    22 Patients: Non-Dialysis CKD stage 3.

    22 Patients: Non-dialysis CKD stage 4/5.

    Total: 44 Patients

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    Asthma

  • Study Aim:

    To understand the safety and efficacy of the drug AZD1402 in adults with moderate asthma, who regularly use inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs).

  • Sponsor/Owner:

    AstraZeneca

  • Goal:

    20 patients

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    COPD

  • Study Aim:

    A study to discover whether a new investigational medication (Tozorakimab) could help reduce the number of exacerbations for people with COPD.

  • Sponsor/Owner:

    AstraZeneca

  • Goal:

    30+ patients with symptomatic COPD

See Study Details Right Arrow

Key Study Information:

  • Treatment Area:

    RSV

  • Study Aim:

    To understand how strongly babies can be protected from serious illness due to RSV infection (respiratory syncytial virus) by giving them a single antibody dose.

  • Sponsor/Owner:

    LabCorp/SANOFI

  • Goal:

    Aims to recruit 12,000 babies <1 year old

See Study Details Right Arrow